FDA Advisory Committee Recommends Approval of Merck’s Vorapaxar for Prevention of Thrombotic Events in Post-MI Patients January 31, 2014 Filed under: Trends-in-Medicine
FDA Advisory Committee Recommends Against Expanded Approval of J&J’s Xarelto (Rivaroxaban) for ACS Therapy January 31, 2014 Filed under: Trends-in-Medicine